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Although systemic amyloidosis of amyloid-associated protein (AA) type (secondary or reactive amyloidosis) frequently involves
the liver, it rarely causes clinically apparent liver disease. Mild elevation of alkaline phosphatase and hepatomegaly are the most
common biochemical and clinical ﬁndings, respectively. We report a case of systemic amyloidosis of AA type, which clinically
presented as subacute hepatic failure and resulted in a fatal clinical course in a 69-year-old man. To the best of our knowledge,
this is the ﬁfth case of hepatic amyloidosis of AA type that clinically presented as fatal subacute hepatic failure, an unusual clinical
presentation for hepatic involvement by systemic AA-type amyloid.
1.Introduction
Hepaticinvolvementinsystemicamyloidosisiscommonand
occurs in myeloma-related (AL) (primary amyloidosis) and
amyloid-associated (AA) (secondary or reactive) types of
the disease. However signiﬁcant clinical evidence of hepatic
dysfunction is not common and the patients rarely exhibit
clinical manifestations. These may include hepatomegaly,
mild jaundice, and, rarely, severe cholestasis. Portal hyper-
tension may complicate hepatic amyloidosis, and subcap-
sular hematoma and spontaneous rupture of liver were
reported [1]. Subacute and acute, fulminant liver failures
were previously reported, particularly in association with
AL-type amyloidosis in the setting of myeloma [2]. Herein,
we present an unusual case of AA-type amyloidosis with
massive hepatic involvement and subacute liver failure—
a clinical presentation rarely seen in secondary hepatic
amyloidosis.
2.CaseReport
A previously healthy 69-year-old man presented with history
of progressively increasing jaundice for six weeks and
abdominaldistensionwithswellingofthefeetforfourweeks.
He also had symptoms of fatigue, poor appetite, and mild
generalized itching. His past medical history was unremark-
able, with no previous history of chronic liver disease. Upon
physical examination, the patient had normal built exhibited
severejaundice,bilateralpittinglower-limbedema,left-sided
moderate pleural eﬀusion, short apical systolic murmur, and
massive hepatomegaly, associated also with marked ascites
without signs of overt congestive heart failure. Complete
blood count and serum electrolytes were within normal
limits. Laboratory studies showed blood urea 3.9mmol/l
(normal range 3–9.2), creatinine 64 μmol/l (45–110), total
bilirubin of 196μmol/l (3.4–20.5), serum albumin 24g/l
(35–50), INR 3.2, alkaline phosphatase 256 IU/l (40–150),
γ-glutamyltransferase 136 (2–30), alanine aminotransferase
28IU/l (5–55), and aspartate aminotransferase 70IU/l (5–
34). The C-reactive protein was elevated, and immunoglob-
ulin levels were normal with immunoglobulin (Ig) G 12
g/l (7.51–15.60), IgA 3.15g/l (0.82–4.53), and IgM 0.52g/l
(0.46–3.04). Serum protein electrophoresis was normal and
with negative urine measurement of Bence-Jones protein.
Alpha-fetoprotein was within normal range. Viral serology
for HCV was negative, while HBcAb and HBs-Ab were pos-
itive. Rheumatoid factor, antinuclear antibody, antismooth
muscle antibody, and anti-DNA antibody were all negative.2 Pathology Research International
Twenty-four-hour urinary protein excretion was 0.068g/l.
Abdominal ultrasonography revealed hepatomegaly with no
focal liver lesions and normal intra- and extrahepatic bile
ducts. The size of the spleen was normal, and the inferior
vena cava as well as hepatic, portal, and superior mesenteric
veins were patent. Transthoracic echocardiography showed
severe concentric left ventricular hypertrophy with diastolic
dysfunction, normal systolic function with ejection fraction
of >55%, a marginally elevated right ventricular systolic
pressure at 30–40mmHg, and a small pericardial eﬀusion.
Ascetictapwasperformed,revealingnormalwhitecell-count
and total protein of 7.6g/l. Transjugular liver biopsy was
performed.
Five-micron sections from the 10% formalin-ﬁxed
and paraﬃn-embedded tissue were examined. Histological
examination was performed on haematoxylin and eosin,
periodic acid Schiﬀ with and without diastase pretreat-
ment, Masson Trichome, van Gieson, and reticulin special
stains. Persian blue and rhodanine special stains were
also performed to evaluate the hepatic iron and copper
contents, respectively. Congo Red special stain for amyloid
was performed on 8-micron sections. Light microscopy
revealed liver tissue with diﬀuse, panacinar eﬀacement of
the hepatic architecture by extensive, pale eosinophilic,
homogenous, and acellular material, causing severe loss
of liver parenchyma. This material was predominantly
deposited perisinusoidally in linear pattern (sinusoidal pat-
tern) (Figure 1). Focally, deposition of the material was
also identiﬁed in the interlobular arterioles (Figure 2).
The material was stained positive with Congo Red and
displayed green birefringence when viewed under polarized
light, conﬁrming amyloid deposition. Scattered residual,
atrophic hepatocytes and bile ducts were present (Figure 3).
Focal mild lymphocytic chronic portal inﬂammation was
noted. Two additional ancillary studies were performed: (1)
immunohistochemical staining for AA-type amyloid (Dilu-
tion1:100,clonemc1,Dako,Denmark),whichwasdiﬀusely
positive (Figure 4), (2) electron microscopy examination
using formalin-ﬁxed and paraﬃn-embedded tissue, which
revealed randomly distributed nonbranching rigid ﬁbrillary
structures of 7 to 10nm in diameter ultrastructural features
compatible with amyloid.
The patient’s clinical condition rapidly deteriorated over
the subsequent two weeks, and he developed fulminant
liver failure with marked elevation of the total bilirubin
(645μmol/l), INR (4.4), and prothrombin 45.2 (NR 7.2–
10.4sec) as well as partial thromboplastin 72.5 (NR 26.1–
37.3sec) times. These were associated with the development
of acute renal failure, the blood urea was 13.1mmol/l, and
creatinine was 141μmol/l. The patient’s condition continued
to deteriorate further and he expired on day 54 of his initial
presentation.
3. Discussion
Amyloidosis is a medical condition of abnormal protein
metabolism, characterized by extracellular deposition of
misfolded, normally soluble proteins and polypeptides in
ﬁbrillary form. Amyloidosis is classiﬁed on the basis of the
Figure 1: Liver tissue with massive deposition of extracellular
pale eosinophilic amyloid material (H&E, × 200). The amyloid
deposition exhibits predominantly a sinusoidal pattern (Inset,
Periodic Acid Schiﬀ stain, × 400).
Figure 2:Theamyloidmaterialisstainedorange-redbyCongoRed
stain. Focal deposition of amyloid was identiﬁed in the arterioles in
the portal tracts (arrows) (× 400).
chemical composition of the amyloid ﬁbrils and their pre-
cursor protein to morphologically identical but chemically
diﬀerenttypes.Thetwoprincipletypesofamyloidosisare(1)
myeloma-associated (AL) (primary) amyloidosis, which is
associated with plasma cell dyscrasias and malignant B-cell-
type lymphoproliferative malignancies and characterized by
the deposition of the variable region of the immunoglobulin
kappa or lambda light chains and (2) amyloid-associated
(AA)(secondaryorreactive)amyloidosis,whichisassociated
with chronic infectious and noninfectious inﬂammatory
conditions, Hodgkin lymphoma, and non-lymphoid malig-
nancies and characterized by the deposition of amyloid A
ﬁbrils, which are derived from the serum AA precursor
protein. Both types can be localized or systemic. The liver
is commonly involved by systemic amyloidosis. Usually,
hepatic amyloidosis is not associated with signiﬁcant liver
dysfunction and the most common biochemical and clinical
presentations of hepatic amyloidosis are elevation in alkaline
phosphatase levels and hepatomegaly, respectively [3]. Hep-
atic failure is not a common consequence of hepatic amyloi-
dosis. Rare but well-documented cases of fatal subacute and
acute fulminant hepatic failures were previously reported
in associated with myloma-assocaited (AL) amyloidosis [2,
4, 5]. However, hepatic failure is exceedingly rare in the
setting of liver involvement with amyloid-associated (AA)
amyloidosis. To the best of our knowledge, only four cases
of hepatic AA amyloidosis resulting in liver failure were
reported in the English literature [6–9]. In the presentPathology Research International 3
Figure 3: Scattered atrophic hepatocyte plates present within the
massive amount of amyloid material (arrow) (H&E, × 400).
case, the patient had no history of chronic inﬂammatory
conditions or malignancy. He had no family history of
amyloidosis. The clinical presentation of subacute liver
failure with rapid deterioration in clinical condition and
subsequent fatality is unusual for hepatic involvement by
AA amyloidosis. Hepatic amyloid deposition in systemic AA
amyloidosis is typically associated with signiﬁcant amyloid
deposition in other organs, and carries a poor prognosis.
I nas t u d yb yL o v a te ta l .[ 10], one hundred and thirty
eight patients with AA amyloidosis were studied, in which
25 (18%) had hepatic involvement; in that study, there was
signiﬁcantdropintheﬁve-yearsurvivalfrom72%inpatients
without liver involvement to 43% in patients with liver
involvement. The presences of congestive heart failure, high
bilirubin level, and high platelet count have been found to
be predictors of poor prognosis in these patients [9]. Our
patienthad twoof thethreepoor prognostic factors;thehigh
bilirubin and cardiac involvement. Although the patient was
positive for HBc-Ab, he had high titers of HBsAb denoting
immunity. Amyloidosis is rarely being considered in the
diﬀerential diagnosis of acute or fulminant liver failure. In
fact, in a study of 98 patients, amyloidosis was considered
in the diﬀerential diagnosis only in 14 (14%) patients before
liver biopsy [9]. High CRP and a low serum albumin level
have been shown to be indicators of hepatic involvement in
amyloidosis [6].
The amyloid characteristically appears acellular pale
eosinophilic and amorphous on routine hematoxylin and
eosin stain, and, when stained with Congo Red, it exhibits
greenbirefringenceunderpolarization.Diﬀerenthistological
patterns of distribution were described in hepatic amyloi-
dosis. These include vascular pattern, in which mainly the
hepatic arteries and arterioles are involved, sinusoidal/linear
pattern in which the amyloid deposits in the space of Disse
along the hepatic sinusoids, and globular pattern that is
characterized by the presence of 1–40μmr o u n dg l o b u l e so f
amyloid in portal tracts, space of Disse, and occasionally
in the cytoplasm of the hepatocytes [11]. These patterns of
hepatic amyloid deposition occur singly or in conjunction
and cannot be used to distinguish between the various
forms of systemic amyloidosis. In a recent study Makhlouf
and Goodman [12] suggested that the globular form of
amyloidosis represents an early stage of hepatic involvement
by systemic amyloidosis.
Figure 4: Positive immunohistochemical staining for amyloid-
associated protein, highlighting the sinusoidal linear deposition of
amyloid (× 400).
In conclusion, this case describes a patient with systemic
AA-type amyloidosis, who presented with fatal subacute
liver, an unusual clinical presentation of the secondary
hepatic amyloidosis. Hepatic amyloidosis should always be
considered in the diﬀerential diagnosis of acute liver failure
especially in patients with features suggestive of inﬁltrat-
ing disorder, such as massive hepatomegaly, intrahepatic
cholestasis, unusually low serum albumin, and evidence of
cardiac or other organs being involved. Liver biopsy to
conﬁrm the diagnosis may be warranted.
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